ClinicalTrials.gg
RecruitingNCT03662373INSIDEUpdated Aug 11, 2025

Innovative SolutIons for DosimEtry in Hadrontherapy (INSIDE)

An observational study in Particle Therapy, sponsored by CNAO National Center of Oncological Hadrontherapy. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by CNAO National Center of Oncological Hadrontherapy · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Study summary

The study aim is to test the clinical feasibility and effectiveness of an online qualitative monitoring device named INSIDE system during hadrontherapy treatments.

This instrumentation is composed by detectors able to acquire secondary signals generated by the interaction of the primary beam with human tissues. From these measurements performed during irradiation, the INSIDE system estimates the particle beam range inside the patient's body and check the compliance of the ongoing treatment with the clinical prescription, with the aim to optimize the delivered dose.

The study aims to longitudinally monitor patients treated with hadrontherapy at the Italian National Centre of Oncological Hadrontherapy (CNAO) in Pavia in order to:

  • evaluate the stability of the INSIDE system response and the significance of the monitoring measurement;
  • study the clinical tolerances between ongoing and prescribed treatments within which the differences in particle range are not clinically relevant;
  • assess what impact an instrument such as the INSIDE system can have on the clinical routine;
  • evaluate the benefits of such a monitoring system with respect to treatment planning constraints.
Read the detailed description

A treatment monitoring instrumentation is highly demanded to maximize the benefits of hadrontherapy from the increased conformation of the released dose to the tumor volume with respect to the conventional radiotherapy.

Since almost all the energy of the charged particles is deposited in the end of their track (Bragg Peak region), the verification of the particle range by experimental measurements, performed during treatment delivery, can help to increase the therapy effectiveness while better sparing healthy tissues.

The INSIDE system is an innovative bi-modal instrumentation consisting of an in-beam Positron Emission Tomography (PET) scanner, to detect annihilation photons coming from positron isotope emitters, and a Dose Profiler to collect signals from charged particles emitted during treatment (e.g. protons in the case of carbon ion treatments).

The in-beam PET scanner is composed by two opposite panels of detectors placed above and below the patient bed, respectively. The Dose Profiler is positioned above the patient with an angle of 60°, forwardly with respect to the beam direction.

The INSIDE system is a passive instrumentation, i.e. no additional dose has to be released to the patient for particle range verification.

The INSIDE detectors are mounted on a mobile support and, immediately before the treatment delivery, they will be placed around the patient in the acquisition position, thanks to a dedicated hooking system designed to guarantee the maximum precision and accuracy in the particle range verification.

The INSIDE system mechanics is compatible with multi fields irradiation of patients affected by pathologies of Head-and-Neck and Brain districts.

In the clinical trial, patients affected by four selected pathologies will be included: meningioma and nasopharynx cancers treated with proton beams, Adenoid Cystic Carcinoma (ACC) and clival chordoma treated with carbon ion beams. These were chosen in order to study both projectile particles available at the CNAO centre (i.e., protons and carbon ions), and target specific pathologies which should most benefit from the range monitoring provided by the INSIDE system. Among them are cancers for which an early response is commonly observed and tumors which are located near cavities that can be filled with either water-like material (such as cancerous mass and inflamed tissues) or air.

The patients will undergo a longitudinal protocol of measurements in order to verify the agreement between the ongoing treatment and the prescription throughout the complete treatment period (lasting in average about 4-6 weeks for the selected pathologies).

02

Conditions studied

  • Particle Therapy

Keywords

  • on line monitoring
  • PET in beam
  • Hadrontherapy
03

In context

Lead sponsor

CNAO National Center of Oncological Hadrontherapy is the lead sponsor of 11 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study population is represented by all patients undergoing to treatment at CNAO, selected on the pathology and on the particle used for their radiation therapy. 40 patients affected by one of the four pathologies foreseen and which can offer morphological variations during treatment cycle.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients treated at CNAO with protons or carbon ions with horizontal beam line.
  • meningioma, ACC, skull base (clivus) chordoma, squamous cellular rhinopharynx carcinoma
  • full compatibility of the INSIDE monitoring system with all beam delivery devices in the established irradiating position
  • all emergency procedures are possible notwithstanding INSIDE system positioned.
  • signed written by patient.

Exclusion criteria

Exclusion Criteria

  • missing
  • not affected by one of the selected pathologies
  • failure of pre-treatment compatibility technical assessment
  • failure of pre-treatment emergency procedures check
  • medical or individual reasons (i.e. short time test needed)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • carbon ions radiation therapy

    the group of patients treated with carbon ion radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria

    Radiation: carbon ions radiation therapy

  • protons radiation therapy

    the group of patients treated with proton radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria

    Radiation: protons radiation therapy

Interventions

  • Radiationcarbon ions radiation therapy

    Carbon ion radiation therapy to treat adenoid cystic carcinoma, skull base (clivus) chordoma.

    Also known as: particle therapy

  • Radiationprotons radiation therapy

    Proton radiation therapy used to treat meningioma and squamocellular rhinopharynx carcinoma

    Also known as: particle therapy

06

What researchers measure

Primary outcomes

  1. particles ranges

    evaluate the quality of treatments in term of data collection and of particles range evaluated with PET scanner and Monte Carlo simulations

    Time frame: average of 5 weeks (as a treatment duration)

  2. particles ranges for each pathology considered

    statistical analysis to assess the evaluations of treatment

    Time frame: 4 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2019 (actual). Primary completion is estimated for Dec 2025, 77 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2018
First posted
Sep 7, 2018
StartActual
Jul 16, 2019
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03662373
Lead sponsor
CNAO National Center of Oncological Hadrontherapy
Responsible party
Sponsor
First posted
Sep 7, 2018
Start date
Jul 16, 2019
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Aug 11, 2025

Study contacts

Viviana Vitolo, MD
Contact
vitolo@cnao.it
00390382078501
Francesca Valvo, MD
Contact
direzionemedica@cnao.it
00390382078501
Viviana Vitolo, MD
principal investigator · CNAO National Center of Oncological Hadrontherapy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion